Table 3.
Patients characteristics in the SCCS analyses
| Characteristic | No. of patients (%) | Age at observation start, mean (SD), Y | Length of prescription, median (range) [IQR], d | Risk period (exposure) | Baseline period (no exposure) | ||
|---|---|---|---|---|---|---|---|
| Incident seizures, No | Total follow-up time, patient-years | Incident seizures, No | Total follow-up time, patient-years | ||||
| 1. Risk of incident seizure associated with antipsychotic exposure | |||||||
| All | 149 (100) | 16.15 (14.03) | 49 (1–2553) [25–78] | 61 | 479.4 | 88 | 1049.9 |
| Male | 119 (79.9) | 17.13 (14.59) | 50 (1–2553) [25–81] | 53 | 408.7 | 66 | 795 |
| Female | 30 (20.1) | 12.23 (10.89) | 28 (1–471) [15–56] | 8 | 70.7 | 22 | 254.9 |
| 2. Risk of incident seizure associated with antipsychotic exposure (excluding patients died during study period) | |||||||
| All | 147 (100) | 15.90 (13.71) | 60 | 469.2 | 87 | 1043.4 | |
| Male | 117 (79.6) | 16.84 (14.23) | 50 (1–2553) [26–81] | 52 | 398.5 | 65 | 788.5 |
| Female | 30 (20.4) | 12.32 (11.51) | 30 (1–1841) [27–65] | 8 | 70.7 | 22 | 254.9 |
| 3. Risk of otitis media associated with antipsychotic exposure (negative control) | |||||||
| All | 334 (100) | 13.44(13.77) | 32 (1–3763) [16–71] | 73 | 972.4 | 261 | 2691.6 |
| Male | 250 (74.8) | 12.32 (13.26) | 42 (1–3763) [21–74] | 54 | 737 | 196 | 2042.3 |
| Female | 84 (25.1) | 16.78 (14.75) | 28 (2–3549) [14–60] | 19 | 235.4 | 65 | 649.3 |